We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Noven Pharmaceuticals' efforts to bring a generic version of Johnson & Johnson's
(J&J) Duragesic transdermal pain patch to market are being deliberately
blocked by a "suspicious" string of citizen petitions, the company
claimed in a recent filing with the FDA.
A new Rhode Island law allowing for the importation of prescription drugs would
provide licenses to Canadian pharmacies -- a plan that represents a new strategy
by states seeking to lower residents' drug costs.
The U.S. Pharmacopeia's (USP) final model guidelines for Medicare drug formularies
maintain the same number of categories and classes as the earlier draft guidelines
-- a move that rebuffs calls by the pharmaceutical industry to give the plan
a comprehensive revision.
Biopure has obtained commitments from institutional and individual investors
to purchase approximately $11.3 million of its common stock for anticipated
net proceeds to Biopure of approximately $10.4 million.
Infinity Pharmaceuticals has entered into a collaborative agreement with Novartis
to jointly design a collection of novel small molecules to be synthesized by
Infinity using its innovative chemical technology platform.
Biotech company Sangamo BioSciences is collaborating with drugmaker Pfizer to
produce enhanced proteins. Financial terms of the agreement were not disclosed.
Oxford BioMedica, a gene therapy company, has entered into an agreement to license
its LentiVector technology to Biogen Idec for use in research activities.
Manhattan Pharmaceuticals has signed a letter of intent to merge with Tarpan
Therapeutics, a privately held, New York-based pharmaceutical company developing
dermatological therapeutics, in an all stock transaction.
Allied Capital finished its buyout of Insight Pharmaceuticals on Dec. 31, 2004,
following an investment of roughly $155 million in the maker of nonprescription
medications.